CLINICAL_TRIALS
trial_result
· 2017-04-07
Clinical Trial Update: RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer [Phase 1, Phase 2]
Summary
A Phase 1/2 study of RAD001 (everolimus) with AV-951 (cediranib) in refractory, metastatic colorectal cancer has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Gastrointestinal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-04-07